The efficacy of levodopa treatment declines in the course of Parkinson's disease: do nondopaminergic lesions play a role?
Agid
Y
Y
INSERM U 289, Hôpital de la Salpêtrière, Paris, France.
Graybiel
A M
AM
Ruberg
M
M
Hirsch
E
E
Blin
J
J
Dubois
B
B
Javoy-Agid
F
F
D001921:Brain / Q000187:drug effects*; D001931:Brain Mapping; D003342:Corpus Striatum / Q000187:drug effects; D006801:Humans; D007980:Levodopa / Q000008:administration & dosage*; D008134:Long-Term Care; D009434:Neural Pathways / Q000187:drug effects; D018377:Neurotransmitter Agents / Q000378:metabolism*; D010300:Parkinson Disease / Q000188:drug therapy*; D011954:Receptors, Dopamine / Q000187:drug effects*; D017981:Receptors, Neurotransmitter / Q000187:drug effects*; D013378:Substantia Nigra / Q000187:drug effects
D018377:Neurotransmitter Agents; D011954:Receptors, Dopamine; D017981:Receptors, Neurotransmitter; D007980:Levodopa